Business Standard

PSAI segment decline pulls down Dr Reddy's Q1 show

Earnings were driven by one-off gains

drugs, medicines, USFDA
Premium

Representative Image

Ujjval Jauhari
Dr Reddy’s below than expected performance for the June quarter was led by a temporary disruption in the manufacturing of the active ingredient. Pharmaceutical services and Active Ingredients (PSAI) segment reported a 10 per cent decline in sales on a year-on-year basis and 33 per cent sequentially. The management, however, said that segments sales would normalize in the September quarter.

Global Generics sales grew 8 per cent year-on-year and 9 per cent sequentially. India and

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 30 2019 | 1:35 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com